In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- OWP Pharmaceuticals to develop schizophrenia drugon October 8, 2020 at 12:03 pm
NAPERVILLE -- OWP Pharmaceuticals Inc. said it has received approval from the U.S. Food and Drug Administration to develop the first liquid formulation of quetiapine fumarate, a drug used to treat ...
- Podcast: Large Family Beset by Schizophreniaon October 6, 2020 at 5:00 pm
Today's guest is Robert Kolker, author of Hidden Valley Road, the true story of a mid-century American family besieged by schizophrenia. Transcript included.
- In a new book, former state Rep. Mindy Greiling talks about her son’s schizophrenia — and her mental health advocacyon October 5, 2020 at 7:13 am
After her son’s diagnosis, Greiling said, “I started working on mental health legislation wherever I encountered it.” ...
- Mattie’s Call issued for missing 57-year-old Atlanta woman with Schizophreniaon October 3, 2020 at 1:05 pm
Police need your help finding a missing 57-year-old Atlanta woman who hasn’t been seen since Friday. The Emory Police Department put out a Mattie’s Call for Tiola Laverne Vaughan.
- IBM joins NIH effort to diagnose schizophrenia using AIon October 2, 2020 at 1:03 pm
IBM says it will join a U.S. National Institutes of Health effort to apply data analysis to finding diagnostic techniques and treatments for schizophrenia.
- Two Sides of Schizophreniaon October 2, 2020 at 6:53 am
I had the opportunity to read an advance copy of a new book, The Essential Schizophrenia Companion, by Robert Francis (with a foreword by Elyn R. Saks, PhD, JD) - a man who has struggled with ...
- Computer model explains altered decision making in schizophreniaon September 29, 2020 at 9:42 am
Scientists have built a computer 'brain circuit', or artificial neural network, that mirrors human decision-making processes and sheds light on how circuits might be altered in psychiatric diseases, a ...
- Europe Schizophrenia Market and Competitive Landscape Report 2020 - ResearchAndMarkets.comon September 29, 2020 at 5:55 am
The "Europe Schizophrenia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
- Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophreniaon September 29, 2020 at 4:24 am
Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.
via Bing News